Bethea ED, Gaj K, Gustafson JL, et al. - In uninfected recipients of HCV-infected donor hearts, researchers ascertained if the development of chronic hepatitis C virus (HCV) infection can be safely prevented pre-emptive administration of pangenotypic direct-acting antiviral therapy. Patients were recruited from November 1, 2017 to November 30, 2018 for this an open-label, single-center, proof-of-concept study. Fifty-five patients have been evaluated for eligibility and 52 consented to enrollment. In patients receiving HCV-infected donor hearts, pre-emptive administration of glecaprevir-pibrentasvir therapy results in expedited organ transplantation, rapid HCV suppression, prevention of chronic HCV infection, and excellent early allograft function. Long-term results are still unknown.